Bausch Health Cos Inc. (NYSE:BHC) Stock Has Consensus Price Target of $8.25

Bausch Health Cos Inc. (NYSE:BHC) has earned an average recommendation of “Reduce” from the seven brokerages that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and six have assigned a hold rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.25.

Several brokerages recently commented on BHC. Royal Bank Of Canada upped their target price on Bausch Health Cos from $9.00 to $10.00 and gave the company a “sector perform” rating in a research report on Thursday, October 29th. Jefferies Financial Group increased their target price on shares of Bausch Health Cos from $6.50 to $8.00 and gave the company a “hold” rating in a research note on Thursday, October 29th. Weiss Ratings reiterated a “sell (d)” rating on shares of Bausch Health Cos in a research report on Thursday, October 29th. Zacks Research lowered shares of Bausch Health Cos from a “strong-buy” rating to a “hold” rating in a research note on Thursday. Finally, Wall Street Zen raised shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 1st.

Bausch Health Cos Price Performance

NYSE BHC opened at $8.20 on Friday. Bausch Health Cos has a 12 month low of $4.33 and a 12 month high of $9.04. The company has a 50-day moving average of $6.40 and a 200-day moving average of $5.74. The company has a market cap of $3.07 billion, a P/E ratio of -3.58 and a beta of 0.30.

Bausch Health Cos (NYSE:BHC) last announced its quarterly earnings data on Wednesday, October 28th. The company reported $1.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.52. Bausch Health Cos had a negative return on equity of 401.73% and a negative net margin of 7.57%. The business had revenue of $2.90 billion during the quarter, compared to analyst estimates of $2.72 billion. As a group, equities research analysts anticipate that Bausch Health Cos will post 4.53 EPS for the current year.

Insiders Place Their Bets

In other news, insider Aimee Lenar sold 36,827 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $7.03, for a total transaction of $258,893.81. Following the completion of the sale, the insider owned 334,853 shares in the company, valued at approximately $2,354,016.59. This trade represents a 9.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 20.67% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in BHC. Ritholtz Wealth Management boosted its holdings in Bausch Health Cos by 6.1% in the third quarter. Ritholtz Wealth Management now owns 192,524 shares of the company’s stock worth $1,122,000 after acquiring an additional 10,984 shares in the last quarter. Lido Advisors LLC increased its holdings in Bausch Health Cos by 421.6% in the 3rd quarter. Lido Advisors LLC now owns 372,508 shares of the company’s stock worth $2,172,000 after acquiring an additional 301,098 shares in the last quarter. Commonwealth Equity Services LLC lifted its position in Bausch Health Cos by 22.7% in the third quarter. Commonwealth Equity Services LLC now owns 12,992 shares of the company’s stock valued at $76,000 after buying an additional 2,400 shares during the last quarter. Chicago Partners Investment Group LLC lifted its stake in Bausch Health Cos by 6,366.3% during the third quarter. Chicago Partners Investment Group LLC now owns 757,203 shares of the company’s stock worth $4,876,000 after purchasing an additional 745,493 shares during the last quarter. Finally, Ascent Group LLC acquired a new position in Bausch Health Cos during the third quarter worth $67,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc (NYSE:BHC) is a multinational specialty pharmaceutical company focused on developing, manufacturing and commercializing branded, generic and over-the-counter medicines. Its portfolio serves several therapeutic areas, including gastroenterology, dermatology, neurology, ophthalmology, hospital products and other specialty-care markets.

The company markets products through businesses such as Salix Pharmaceuticals, Ortho Dermatologics, Solta Medical and its international pharmaceutical operations.